Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for BIIB
271.21
-5.36 (-1.94%)
After Hours: 272.25 +1.04 (0.38%)
Apr 28, 6:06PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 271.06 - 277.28
52 week 223.02 - 333.65
Open 277.09
Vol / Avg. 1.80M/1.76M
Mkt cap 56.83B
P/E 17.01
Div/yield     -
EPS 15.95
Shares 212.12M
Beta 0.79
Inst. own 92%
Jul 19, 2017
Q2 2017 Biogen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 8, 2017
Biogen Inc Annual Shareholders Meeting (Estimated) - 9:00AM EDT - Add to calendar
Jun 7, 2017
Biogen Inc Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Apr 25, 2017
Q1 2017 Biogen Inc Earnings Release
Apr 25, 2017
Q1 2017 Biogen Inc Earnings Call
Mar 6, 2017
Biogen Inc at Cowen Health Care Conference
Feb 22, 2017
Biogen Inc at RBC Capital Markets Healthcare Conference
Feb 15, 2017
Biogen Inc at Leerink Partners Global Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin 26.59% 32.28%
Operating margin 36.44% 44.99%
EBITD margin - 55.45%
Return on average assets 13.61% 17.44%
Return on average equity 25.39% 34.42%
Employees 7,400 -
CDP Score - B

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; BIIB061; BIIB054; BIIB067, and BIIB068.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 68
Bio & Compensation  - Reuters
Michel Vounatsos Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 55
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 58
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 60
Bio & Compensation  - Reuters
Michael D. Ehlers M.D., Ph.D. Executive Vice President, Head - Research and Development
Age: 48
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology , Business Solutions and Corporate Affairs
Age: 54
Bio & Compensation  - Reuters
Paul McKenzie Ph.D. Executive Vice President - Pharmaceutical Operations & Technology
Age: 51
Bio & Compensation  - Reuters
Alfred W. Sandrock Jr., M.D., Ph.D. Executive Vice President - Neurology Discovery and Development and Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters
Anirvan Ghosh Ph.D. Senior Vice President - Research and Early Development
Bio & Compensation  - Reuters